Kisho

ZielBio Incorporated — Rare Disease Pipeline | Kisho

ZielBio Incorporated

Other

Orphan Designations

0 approved, 2 designated

FDA Approvals

Active Trials

Rare Diseases

across 3 areas

News (30d)

Quiet

ZielBio Incorporated is a company with 2 orphan drug designations across 2 rare diseases.

Competitive Landscape

Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.

Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA

Approved: 0

In Trials: 0

Designated Only: 2

2 total diseases

Disease	Drug(s)	Stage
cholangiocarcinoma	a humanized immunoglobulin IgG1 antibody with a kappa light chain (LC) which has high selectivity and specificity for cancer-specific plectin	Des.TrialAppr.
malignant pancreatic neoplasm	a humanized immunoglobulin IgG1 antibody with a kappa light chain (LC) with high selectivity and specificity for cancer-specific plectin	Des.TrialAppr.